Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
Xencor, Inc.
Xencor, Inc.
Atavistik Bio, Inc
Compass Therapeutics
PMV Pharmaceuticals, Inc
Mayo Clinic
University of Michigan Rogel Cancer Center
Alterome Therapeutics, Inc.
Rutgers, The State University of New Jersey
Eli Lilly and Company
BeOne Medicines
Bayer
Psyence Australia Pty Ltd
Genmab
Jazz Pharmaceuticals
Rutgers, The State University of New Jersey
Kaiser Permanente
Children's Oncology Group
Duke University
AstraZeneca
Myeloid Therapeutics
Tizona Therapeutics, Inc
BioNTech SE
IDEAYA Biosciences
MacroGenics
Daiichi Sankyo
Doma Biopharmaceutical(Suzhou)Co., Ltd.
Second Life Therapeutics
Medical College of Wisconsin
Mayo Clinic
GlaxoSmithKline
Sairopa B.V.
Wake Forest University Health Sciences
Tanabe Pharma America, Inc.
NeoTX Therapeutics Ltd.
West China Hospital
Tempus AI
UNC Lineberger Comprehensive Cancer Center
Incyte Corporation
Vanderbilt-Ingram Cancer Center
Tempest Therapeutics
National Institutes of Health Clinical Center (CC)
Pfizer
Exelixis
Incyte Corporation
Merck Sharp & Dohme LLC
Cancer Research UK
858 Therapeutics, Inc.
Totus Medicines
NuCana plc
Marengo Therapeutics, Inc.